paywalled: Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?

Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients? 

Abstract

Aim:  The effect of systematic retroperitoneal lymphadenectomy (SRL) remains controversial in patients with advanced epithelial ovarian cancer (aEOC) who are optimally debulked.

Conclusion:  Our data suggest that aEOC patients with optimal cytoreduction who underwent SRL did not show a significant improvement in survival irrespective of each histological type.

Advanced Ovarian Cancer -- A Clinical Context Report - in Clinical Context, Ovarian Cancer from MedPage Today (overview: surgery, treatments, CA125...)

open access: JNCI - Predicting the Value of Indexing Symptoms for Ovarian Cancer

Charities Listings (ovarian cancer) Canada - government of Canada website including tax return information

Canada Revenue Agency

www.cra.gc.ca

Institutional links

Basic Search Results

Statistics and data on the Charities and Giving Web pages are compiled by the Charities Directorate of the Canada Revenue Agency (CRA) for the sole purpose of providing the public with direct access to information about charities in Canada.

The CRA is not responsible for the use and manipulation by any persons of this information.
Charity Status: Canadian Registered Charities
Charity Name: ovarian cancer

A search using the information shown above gave this result:
5 matches found.

Charity Name: FONDATION DU CANCER HEREDITAIRE DU SEIN ET DES OVAIRES/HEREDITARY BREAST AND OVARIAN CANCER FOUNDATION / 883465304RR0001

Charity Status: Registered

Effective Date of Status: 2003-10-15

Sanction: N/A

Address: 5791 FERNCROFT ROAD

City: HAMPSTEAD Province/Territory/Other: QUEBEC Country: CA

Postal Code/Zip Code: H3X1C6

Charity Type: Health

Category: Services Other Than Hospitals

Information Return: T3010 Return

Charity Name: HEREDITARY BREAST OVARIAN CANCER SOCIETY OF ALBERTA / 856019336RR0001

Charity Status: Registered

Effective Date of Status: 2005-01-01

Sanction: N/A

Address: 114 11728 KINGSWAY AVE

City: EDMONTON Province/Territory/Other: ALBERTA Country: CA

Postal Code/Zip Code: T5G0X5

Charity Type: Health

Category: Services Other Than Hospitals

Information Return: T3010 Return

Charity Name: Ovarian Cancer Awareness & Treatment in Saskatchewan Corp. / 800916694RR0001

Charity Status: Registered

Effective Date of Status: 2010-01-01

Sanction: N/A

Address: 700-1914 HAMILTON ST

City: REGINA Province/Territory/Other: SASKATCHEWAN Country: CA

Postal Code/Zip Code: S4P3N6

Charity Type: Health

Category: Services Other Than Hospitals

Information Return: T3010 Return

Charity Name: Ovarian Cancer Canada/Cancer de l'Ovaire Canada / 872974845RR0001

Charity Status: Registered

Effective Date of Status: 1998-08-01

Sanction: N/A

Address: 145 FRONT ST EAST SUITE 101

City: TORONTO Province/Territory/Other: ONTARIO Country: CA

Postal Code/Zip Code: M5A1E3

Charity Type: Health

Category: Services Other Than Hospitals

Information Return: T3010 Return
direct link - compensation section 

What was the charity's total expenditure on all compensation in the fiscal period?

$ 1,420,438

Charity Name: THE CAROL ANNIBALE OVARIAN CANCER FOUNDATION / 863136321RR0001

Charity Status: Registered

Effective Date of Status: 2000-08-11

Sanction: N/A

Address: 74 MUZICH PLACE

City: WOOBRIDGE Province/Territory/Other: ONTARIO Country: CA

Postal Code/Zip Code: L4L9C5

Charity Type: Health

Category: Services Other Than Hospitals

Information Return: T3010 Return

Diffusion-weighted Imaging of Peritoneal Disease for Noninvasive Staging of Advanced Ovarian Cancer1 — RadioGraphics

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer - press release

".... Accordingly, Roche and Genentech have indicated that they plan to further analyze the data, including subset analyses in the coming months. Following these analyses, they expect to make a portfolio decision regarding whether, or to what extent, they will continue development of GDC-0449 in advanced ovarian cancer.

“While we await the final analysis of the data from this advanced ovarian cancer study, we remain optimistic about the continued evaluation of GDC-0449 in tumors such as basal cell carcinoma”

No obvious new safety signals were observed in patients treated with GDC-0449. It is expected that data from this Phase II study will be submitted for presentation at an upcoming medical meeting....cont'd